AstraZeneca: a change in story

AstraZeneca has dodged a bullet after US regulators allowed the group’s controversial cholesterol-lowering drug, Crestor, to remain on the market. Even better for Astra, the Food and Drug Administration asked for minimal changes in the warning label for physicians. But the damage has already been done, and Crestor will never deliver the growth investors once expected. The drug’s market share has already fallen. While the group’s current 6% share of the $23bn market for cholesterol lowering drugs...